camptothecin has been researched along with veliparib in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 12 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Agama, KK; Doroshow, JH; Pommier, Y; Regairaz, M; Seiler, JA; Zhang, YW | 1 |
| Aloyz, R; Davidson, D; Panasci, L; Wang, Y | 1 |
| El-Rayes, B; Gao, H; Landry, J; Shelton, JW; Shu, HK; Wang, L; Waxweiler, TV; Xu, Y | 1 |
| McGregor, N; Pienta, KJ; Wang, X; Wu, M; Zhang, J | 1 |
| Doroshow, JH; Ji, J; Morris, J; Murai, J; Pommier, Y; Takeda, S; Zhang, Y | 1 |
| Bahrami, A; Benavente, C; Bradley, C; Calabrese, C; Caufield, W; Dyer, MA; Freeman, BB; Gordon, B; Goshorn, R; Griffiths, LM; Hatfield, MJ; Karlström, Å; Loh, A; Miller, GM; Pappo, A; Potter, PM; Sablauer, A; Shelat, AA; Shirinifard, A; Snyder, SE; Stewart, E; Thiagarajan, S; Tsurkan, L; Twarog, NR; Wu, J | 1 |
| Boerner, JL; Boerner, SA; Burger, A; Heilbrun, L; LoRusso, PM; Mueller, KL; Nechiporchik, N; Polin, L; Stark, K; Zoratti, GL | 1 |
| Bell, T; Boerner, JL; Boerner, SA; Bowditch, A; Burger, A; Cai, D; Chen, AP; Cleary, JM; Ferry-Galow, K; Heilbrun, LK; Ji, J; Kinders, RJ; Li, J; LoRusso, PM; Marrero, AM; Parchment, RE; Pilat, MJ; Rubinstein, L; Sausville, EA; Shapiro, GI; Smith, D; Tolaney, SM; Wolanski, A; Zhang, J; Zhang, Y | 1 |
| Das, BB; Das, SK; Ghosh, A; Jana, B; Majumdar, P; Rehman, I; Sengupta, S | 1 |
| Krishnan, V; Liem, N; Peethala, PC; Subhash, VV; Tan, SH; Yan, FL; Yeo, MS; Yong, WP | 1 |
| Balasubramanian, P; Chen, AP; Evrard, YA; Kinders, RJ; Kummar, S; Wang, L | 1 |
| Beck, JT; Berlin, JD; Cubillo Gracian, A; Deming, DA; Elez Fernandez, E; Garcia-Alfonso, P; Gorbunova, V; Hofheinz, RD; Luo, Y; Mangel, L; Nechaeva, M; Ramanathan, RK; Sullivan, D; Torres, AH | 1 |
1 review(s) available for camptothecin and veliparib
| Article | Year |
|---|---|
Promise and limits of the CellSearch platform for evaluating pharmacodynamics in circulating tumor cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biomarkers, Tumor; Camptothecin; Clinical Trials as Topic; Cyclophosphamide; Epithelial Cell Adhesion Molecule; Humans; Irinotecan; Neoplasms; Neoplastic Cells, Circulating; Reproducibility of Results; Software; Specimen Handling; Treatment Outcome | 2016 |
2 trial(s) available for camptothecin and veliparib
| Article | Year |
|---|---|
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Camptothecin; Cell Cycle Proteins; DNA Repair; Female; Histones; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Nuclear Proteins; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases | 2016 |
A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bevacizumab; Camptothecin; Colorectal Neoplasms; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Progression-Free Survival | 2019 |
9 other study(ies) available for camptothecin and veliparib
| Article | Year |
|---|---|
Poly(ADP-ribose) polymerase and XPF-ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Camptothecin; Cell Line, Tumor; DNA Damage; DNA Repair; DNA Replication; DNA Topoisomerases, Type I; DNA-Binding Proteins; Endonucleases; Enzyme Inhibitors; Histones; Humans; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Topoisomerase I Inhibitors; Transcription, Genetic | 2011 |
The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzimidazoles; Blotting, Western; Camptothecin; Cell Proliferation; Colonic Neoplasms; Drug Synergism; Flow Cytometry; Humans; Irinotecan; Poly(ADP-ribose) Polymerase Inhibitors; Tumor Cells, Cultured | 2013 |
In vitro and in vivo enhancement of chemoradiation using the oral PARP inhibitor ABT-888 in colorectal cancer cells.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Camptothecin; Chemoradiotherapy; Colorectal Neoplasms; Comet Assay; DNA Damage; Female; Fluorouracil; HCT116 Cells; Histones; HT29 Cells; Humans; Irinotecan; Mice; Mice, Nude; Neoplasm Proteins; Organoplatinum Compounds; Oxaliplatin; Poly(ADP-ribose) Polymerase Inhibitors; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Dynamic regulation of Rad51 by E2F1 and p53 in prostate cancer cells upon drug-induced DNA damage under hypoxia.
Topics: Antineoplastic Agents; Base Sequence; Benzimidazoles; Camptothecin; Cell Hypoxia; Cell Line, Tumor; DNA Damage; DNA Primers; DNA, Neoplasm; E2F1 Transcription Factor; Humans; Irinotecan; Male; Polymerase Chain Reaction; Prostatic Neoplasms; Rad51 Recombinase; Tumor Suppressor Protein p53; Up-Regulation | 2014 |
Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Survival; Chickens; Dacarbazine; DNA Damage; DNA Repair; Drug Synergism; Enzyme Inhibitors; Humans; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide | 2014 |
Targeting the DNA repair pathway in Ewing sarcoma.
Topics: Animals; Benzimidazoles; Camptothecin; Cell Death; Cell Line, Tumor; Dacarbazine; DNA Breaks, Double-Stranded; DNA Repair; Drug Synergism; Enzyme Inhibitors; Irinotecan; Mice, Nude; Molecular Targeted Therapy; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Sarcoma, Ewing; Temozolomide; Xenograft Model Antitumor Assays | 2014 |
Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Camptothecin; Cell Line, Tumor; Cell Survival; DNA Breaks, Double-Stranded; DNA Repair; DNA-Binding Proteins; Drug Synergism; Endonucleases; Female; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Mice; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Topoisomerase I Inhibitors; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2015 |
Poly(ADP-ribose) polymers regulate DNA topoisomerase I (Top1) nuclear dynamics and camptothecin sensitivity in living cells.
Topics: Benzimidazoles; Camptothecin; Cell Nucleolus; Cell Nucleus; Cell Survival; Diffusion; DNA; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Fluorescence Recovery After Photobleaching; Green Fluorescent Proteins; HCT116 Cells; Humans; Kinetics; Mutant Proteins; Plasmids; Poly Adenosine Diphosphate Ribose; Poly(ADP-ribose) Polymerase Inhibitors | 2016 |
ATM Expression Predicts Veliparib and Irinotecan Sensitivity in Gastric Cancer by Mediating P53-Independent Regulation of Cell Cycle and Apoptosis.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Ataxia Telangiectasia Mutated Proteins; Benzimidazoles; Camptothecin; Cell Cycle; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression; Histones; Humans; Inhibitory Concentration 50; Irinotecan; Oncogene Protein p21(ras); Phosphorylation; Proto-Oncogene Proteins; Stomach Neoplasms; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2016 |